Esperion Therapeutics Secures $70,000,000 New Funding Round

  • Feed Type
  • Date
    6/26/2013
  • Company Name
    Esperion Therapeutics
  • Mailing Address
    46701 Commerce Center Drive Plymouth, MI 48170
  • Company Description
    Esperion Therapeutics, Inc. (NASDAQ: ESPR) discovers and develops pharmaceutical products for the treatment of cardiovascular and metabolic diseases. Esperion intends to commercialize a novel class of drugs that focuses on a new treatment approach called HDL Therapy, which is based on the Company’s understanding of high-density lipoprotein, or HDL, function.
  • Website
    http://www.esperion.com
  • Transaction Type
    IPO
  • Transaction Amount
    $70,000,000
  • Transaction Round
    Undisclosed
  • Proceeds Purposes
    Proceeds purposes are on file with company statements at the SEC.
  • M&A Terms

By posting a comment, you agree to our terms and conditions.